GROTON, Mass.--(BUSINESS WIRE)--Neosoma, Inc., an innovative medical technology company focused on helping clinicians advance the treatment of brain cancers, announces today it has appointed Debbie Millin and Frederick Driscoll to its board of directors.
“Key to executing on our strategy is ensuring that the company has a diverse and experienced board of directors,” said Ken Kolodziej, Neosoma’s CEO and Co-Founder. “Debbie and Fred each bring a wealth of operational and strategic expertise to scaling software and life sciences businesses, as well as a passion for our mission. Together, their involvement sets Neosoma up well for our next phase of growth; I couldn’t be more excited.”
Debbie Millin has made a career of scaling rapid-growth companies in disruptive industries, leading two separate companies to be the #1 fastest growing private company in Massachusetts. She served as the founding Chief Operating Officer at Globalization Partners (G-P), where she grew the company from 3 people to a valuation of $4.2 billion, and received multiple awards for the company's extraordinary growth, innovation, and culture. Debbie also serves on multiple committees for the Board of Trustees at the Museum of Science in Boston, and the Harvard Club of Boston. She is an alumna of Bentley University and Harvard Business School.
Frederick Driscoll is an accomplished healthcare executive with more than 25 years of financial management of life sciences companies. Mr. Driscoll served as Chief Financial Officer at Flexion Therapeutics (Flexion) in 2021 where he was a member of the merger and acquisitions executive team that executed the $1bn sale of the Company to Pacira BioSciences. He previously served as Flexion’s Chief Financial Officer from 2013 to 2017; during his tenure he spearheaded an initial public offering in 2014 and was at the financial helm through the commercial launch of ZILRETTA. Mr. Driscoll earned a B.S. in accounting and finance from Bentley University and currently serves as a member of the board of directors of Cue Biopharma, Cellectar Biosciences, Inc. and MEI Pharma.
Neosoma is focused on advancing the treatment of brain cancers through an integrated portfolio of innovative, artificial intelligence-based software products combined with a Clinical Management Software Platform. Neosoma’s comprehensive SaaS solution is first-of-its-kind technology in the neuro-oncology space, helping physicians to make better treatment decisions with the goal of improving clinical outcomes.
Starting with its initial software-based medical device, Neosoma HGG, the company is developing a full suite of software technologies to become the global leader in the neuro-oncology field.
For more information, visit: https://neosomainc.com